While menopausal hormone therapy was once accepted as the ideal approach for optimizing changes associated with menopause, prospective randomized clinical trials have challenged that view. The result has led to a marked decrease in the use of such therapy and an intense search for alternatives. This commentary will highlight the progress in vulvovaginal atrophy treatments and what's new on the horizon.